Benoit Haelewyn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Benoit Haelewyn has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Jacques Risso
Institut de Recherche Biomédicale des Armées, IRBA, Equipe de Recherche Subaquatique Opérationnelle (ERSO), Toulon CEDEX 9, 91220 Brétigny-sur-Orge, France
2 shared publications - Hélène N. David
CSSS Alphonse-Desjardins, Centre Hospitalier Affilié Universitaire Hôtel-Dieu de Lévis, Université Laval, Lévis, QC, Canada
1 shared publication - Jacques H. Abraini
CSSS Alphonse-Desjardins, Centre Hospitalier Affilié Universitaire Hôtel-Dieu de Lévis, Université Laval, Lévis, Canada
1 shared publication - Jacques H. Abraini
Institut de Recherche Biomédicale des Armées, Équipe Résidente de Recherche, Subaquatique Opérationnelle, Toulon, France
1 shared publication - Laurent Chazalviel
ERT 1083, UMR 6232, Université de Caen Basse Normandie, CNRS, CEA, Centre CYCERON, B.P. 5229, Boulevard Henri Becquerel, 14074 Caen cedex, France
1 shared publication - Myriam Lecocq
ERT 1083, UMR 6232, Université de Caen Basse Normandie, CNRS, CEA, Centre CYCERON, B.P. 5229, Boulevard Henri Becquerel, 14074 Caen cedex, France
1 shared publication
Latest Publications
- 11 November 2012
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 386 (1) , 91-95
Modulation by the noble gas argon of the catalytic and thrombolytic efficiency of tissue plasminogen activator
Argon has been shown to provide cortical as well as, under certain conditions, subcortical neuroprotection in all models so far (middle cerebral artery occlusion, trauma, neonatal asphyxia, etc.). This has led to the suggestion that argon could be a cost-efficient alternative to xenon, a metabolically inert gas thought to be gold standard in gas pharmacology but whose clinical development suffers its little availability and excessive cost of production. However, whether argon interacts with the thrombolytic agent tissue plasminogen activator, which is the only approved therapy of acute ischemic stroke to date, still remains unknown. This latter point is not trivial since previous data have clearly demonstrated the inhibiting effect of xenon on tPA enzymatic and thrombolytic efficiency and the critical importance of the time at which xenon is administered, during or after ischemia, in order not to block thrombolysis and to obtain neuroprotection. Here, we investigated the effect of argon on tPA enzymatic and thrombolytic efficiency using in vitro methods shown to provide reliable prediction of the in vivo effects of both oxygen and the noble inert gases on tPA-induced thrombolysis. We found that argon has a concentration-dependent dual effect on tPA enzymatic and thrombolytic efficiency. Low and high concentrations of argon of 25 and 75 vol% respectively block and increase tPA enzymatic and thrombolytic efficiency. The possible use of argon at low and high concentrations in the treatment of acute ischemic stroke if given during ischemia or after tPA-induced reperfusion is discussed as regards to its neuroprotectant action and its inhibiting and facilitating effects on tPA-induced thrombolysis. The mechanisms of argon–tPA interactions are also discussed.
- 11 November 2012
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 386 (1) , 91-95
Modulation by the noble gas argon of the catalytic and thrombolytic efficiency of tissue plasminogen activator
Argon has been shown to provide cortical as well as, under certain conditions, subcortical neuroprotection in all models so far (middle cerebral artery occlusion, trauma, neonatal asphyxia, etc.). This has led to the suggestion that argon could be a cost-efficient alternative to xenon, a metabolically inert gas thought to be gold standard in gas pharmacology but whose clinical development suffers its little availability and excessive cost of production. However, whether argon interacts with the thrombolytic agent tissue plasminogen activator, which is the only approved therapy of acute ischemic stroke to date, still remains unknown. This latter point is not trivial since previous data have clearly demonstrated the inhibiting effect of xenon on tPA enzymatic and thrombolytic efficiency and the critical importance of the time at which xenon is administered, during or after ischemia, in order not to block thrombolysis and to obtain neuroprotection. Here, we investigated the effect of argon on tPA enzymatic and thrombolytic efficiency using in vitro methods shown to provide reliable prediction of the in vivo effects of both oxygen and the noble inert gases on tPA-induced thrombolysis. We found that argon has a concentration-dependent dual effect on tPA enzymatic and thrombolytic efficiency. Low and high concentrations of argon of 25 and 75 vol% respectively block and increase tPA enzymatic and thrombolytic efficiency. The possible use of argon at low and high concentrations in the treatment of acute ischemic stroke if given during ischemia or after tPA-induced reperfusion is discussed as regards to its neuroprotectant action and its inhibiting and facilitating effects on tPA-induced thrombolysis. The mechanisms of argon–tPA interactions are also discussed.
- Open Access
- 1 January 2011
- Published by Springer Nature in Medical Gas Research
- Vol. 1 (1) , 2
Moderately delayed post-insult treatment with normobaric hyperoxia reduces excitotoxin-induced neuronal degeneration but increases ischemia-induced brain damage
The use and benefits of normobaric oxygen (NBO) in patients suffering acute ischemic stroke is still controversial.
- 1 January 2011
- Published by Springer Nature in Medical Gas Research
- Vol. 1 (1) , 2
Open AccessModerately delayed post-insult treatment with normobaric hyperoxia reduces excitotoxin-induced neuronal degeneration but increases ischemia-induced brain damage
The use and benefits of normobaric oxygen (NBO) in patients suffering acute ischemic stroke is still controversial.